Lam Research stock swings lower after early pop as Citi, Deutsche Bank lift targets ahead of earnings
22 January 2026
1 min read

Lam Research stock swings lower after early pop as Citi, Deutsche Bank lift targets ahead of earnings

New York, Jan 22, 2026, 11:35 (ET) — Regular session

  • Shares of Lam Research dropped roughly 2.9% by midday, even after climbing to an early peak of $238.20
  • Citi bumped its price target up to $265, while Deutsche Bank raised theirs to $260. Both firms maintained their Buy ratings.
  • Investors are turning their attention to Lam’s quarterly results on January 28 and its guidance on chip-factory spending ahead.

Lam Research shares slipped 2.9% to $221.88 on Thursday, erasing gains from an earlier surge up to $238.20. The semiconductor equipment company’s stock closed $6.52 lower than Wednesday.

The broader chip tools group stayed steady despite the pullback. The VanEck Semiconductor ETF climbed around 0.7%, and the iShares Semiconductor ETF rose about 0.5%. Applied Materials dropped roughly 1%, KLA barely moved, and ASML gained close to 1.7%.

Why it matters now: Lam’s shares have hovered near recent peaks ahead of a wave of analyst reports and an earnings announcement seen as a key test for the stock. On Wednesday, the stock closed at $228.39—just under 1% shy of its previous 52-week high—while trading volume surged. 1

Citi lifted its price target on Lam to $265 from $190 on Thursday, maintaining a Buy rating. According to a note cited by TheFly, the bank views Lam as entering a “Phase 2 upcycle,” with wafer fab equipment spending—essentially the tools chipmakers use to produce semiconductors—moving toward Citi’s bullish $126 billion forecast for 2026. 2

Just a day before, Deutsche Bank’s Melissa Weathers raised her price target to $260 from $195, maintaining a Buy rating. She noted the firm had revised its model ahead of earnings and now expects Lam to deliver results “solidly above Street,” referring to consensus analyst estimates. 3

Not all analysts agree. On Thursday, New Street bumped its price target up to $195 from $140 but stuck with a Neutral rating, MT Newswires reports. 4

Lam, headquartered in Fremont, California, offers etch and deposition equipment essential for chip manufacturing, plus services for its installed machines. The stock’s sudden intraday swing highlights how, as earnings approach, investors are betting not only on current results but also on how 2026 spending will unfold at major chipmakers.

The risk is clear: even solid results might not satisfy investors if the company’s forecast disappoints a market hungry for “upcycle” talk. Signs of delayed orders, pricing pressure, or weaker demand in memory gear could swiftly weigh on the stock.

Lam plans to release its December-quarter earnings on Jan. 28, with a conference call set for 5:00 p.m. Eastern, the company announced. 5

Traders are zeroing in on what comes next. All eyes will be on management’s insights into wafer-fab spending, the timing of customer deliveries, and whether the recent upbeat analyst forecasts actually make it into the guidance — extending beyond the upcoming quarter’s results.

Stock Market Today

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

7 February 2026
Linde plc shares fell 2.5% to $448.24 Friday after reporting Q4 sales up 6% to $8.76 billion and adjusted EPS of $4.20. The company guided 2026 adjusted EPS to $17.40–$17.90, below analyst consensus. JPMorgan downgraded the stock, while Morgan Stanley and UBS raised price targets. Linde repurchased $1.4 billion in shares in Q4 and returned $7.4 billion to shareholders in 2025.
UnitedHealth stock rises as CEO heads to Congress with Obamacare rebate pledge
Previous Story

UnitedHealth stock rises as CEO heads to Congress with Obamacare rebate pledge

IREN stock wobbles after new 2x short ETF debuts — here’s what traders are watching
Next Story

IREN stock wobbles after new 2x short ETF debuts — here’s what traders are watching

Go toTop